Tumour necrosis factor gene polymorphism: A predictive factor for the development of post-transplant lymphoproliferative disease

British Journal of Cancer

Volumn 101, Issue 6, 2009, Pages 1019-1027

  McAulay, K A ^a   Haque, T ^b   Crawford, D H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cytokine; EBV; Polymorphism; PTLD; TNF

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALLELE; ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

HAPLOTYPES; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70249095988     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605278     Document Type: Article

References (37)

1. Babel N, Vergopoulos A, Trappe R, Oertel S, Hammer MM, Karaianov S, Schneider N, Riess H, Papp-Vary M, Neuhaus R, Gondek L, Volk H, Reinke P (2007) Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation 84: 387-391
2. Balkwill F (2006) TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25: 409-416
3. Benden C, Aurora P, Burch M, Cubitt D, Lloyd C, Whitmore P, Neligan SL, Elliott MJ (2005) Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction. J Heart Lung Transplant 24: 2103-2108
4. Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A (2006) The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 132: 326-332
5. Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545
6. Chan FK-M, Siegel RM, Lenardo MJ (2000) Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 13: 419-422
7. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N (2006) Efficacy and safety of rituximab in B-cell post-transplantation lympho-proliferative disorders: results of a prospective multicenter phase 2 study. Blood 107: 3053-3057
8. Choquet S, Oertel S, Leblond V, Riess H, Varoqueaux N, DArken B, Trappe R (2007) Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 86: 599-607
9. Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H, Harrison N, Reid S, Conacher M, Douglas J, Swerdlow AJ (2006) A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 43: 276-282
10. Crawford DH, Swerdlow AJ, Higgins CD, McAulay K, Harrison N, Williams H, Britton K, Macsween KF (2002) Sexual history and Epstein-Barr virus infection. J Infect Dis 186: 731-736
11. Davis JE, Sherritt MA, Bharadwaj M, Morrison LE, Elliott SL, Kear LM, Maddicks-Law J, Kotsimbos T, Gill D, Malouf M, Falk MC, Khanna R, Moss DJ (2004) Determining virological, serological and immunological parameters of EBV infection in the development of PTLD. Int Immunol 16: 983-989
12. Feldmann M (2008) Many cytokines are very useful therapeutic targets in disease. J Clin Invest 118: 3533-3536
13. Grutters JC, Sato H, Pantelidis P, Lagan AL, McGrath DS, Lammers JW, van den Bosch JMM, Wells AU, du Bois RM, Welsh KI (2002) Increased frequency of the uncommon tumor necrosis factor-857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 165: 1119-1124
14. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131
15. Helminen M, Lahdenpohja N, Hurme M (1999) Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis 180: 496-499
16. Hopwood PA, Brooks L, Parratt R, Hunt BJ, Maria B, Alero TJ, Magdi Y, Crawford DH (2002) Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients1. Transplantation 74: 194-202
17. Hurme M, Helminen M (1998) Polymorphism of the IL-1 gene complex in Epstein-Barr virus seronegative and seropositive adult blood donors. Scand J Immunol 48: 219-222
18. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP (2000) Cytokine (TNFa, LTa and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 1: 185-190
19. Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA (2006) Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant 20: 389-393
20. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501
21. Nalesnik MA (2002) Clinicopathologic characteristics of post transplant lymphoproliferative disorders. Recent Results Cancer Res 159: 9-18
22. Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica D, Goeddel DV, Gray PW (1985) Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res 13: 6361-6373
23. Ollier WER (2004) Cytokine genes and disease susceptibility. Cytokine 28: 174-178
24. Opelz G, Dohler B (2004) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4: 222-230
25. Paya C, Fung J, Nalesnik M, Kieff E, Green M, Gores G, Habermann T, Wiesner R, Swinnen L, Woodle E, Bromberg J (1999) Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 68: 1517-1525
26. Pratesi C, Bortolin M, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R, Guidoboni M, Franchin G, Barzan L, Zanussi S, Caruso C, De Paoli P (2006) Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55: 23-30 (Pubitemid 41783289)
27. Riddler SA, Breinig MC, McKnight JL (1994) Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84: 972-984
28. Sato T, Fujieda M, Tanaka E, Miyamura M, Chikamoto H, Hisano M, Akioka Y, Ishiura Y, Dohno S, Maeda A, Hattori M, Wakiguchi H (2008) Monitoring of Epstein-Barr virus load and antibody in pediatric renal transplant patients. Paediatr Int 50: 454-458
29. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S,
30. Finegold MJ, Brenner MK, Rooney CM, Heslop HE (2006) Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108: 2942-2949
31. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ (2006) Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol 133: 293-300
32. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86: 3333-3340
33. Thomas R, McAulay K, Higgins C, Wilkie G, Crawford D (2005) Interferon gamma polymorphisms in posttransplant proliferative disease. Blood 106: 1502-1503
34. Udalova IA, Richardson A, Denys A, Smith C, Ackerman H, Foxwell B, Kwiatkowski D (2000) Functional consequences of a polymorphism affecting NF-kappa B p50-p50 binding to the TNF promoter region. Mol Cell Biol 20: 9113-9119
35. VanBuskirk A, Malik V, Xia D, Pelletier R (2001) A gene polymorphism associated with posttransplant lymphoproliferative disorder. Transplant Proc 33: 1834
36. Wheless SA, Gulley ML, Raab-Traub N, McNeillie P, Neuringer IP, Ford HJ, Aris RM (2008) Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med 178: 1060-1065
37. Wu MS, Huang SP, Chang YT, Shun CT, Chang MC, Lin MT, Wang HS, Lin JT (2002) Tumour necrosis factor-á and interleukin-10 promoter polymorphisms in Epstein-Barr virus associated gastric carcinoma. J Infect Dis 185: 106-109